csirt@kutim:~/threat-intel/cve/CVE-2025-22828

Katalog CVE

CVSS 4.3 · Medium EPSS 2,0%

Kerentanan Exposure of Sensitive Information to an Unauthorized Actor pada apache cloudstack. Skor CVSS 3.1 4.3 (Medium) menurut CISA ADP.

Deskripsi (NVD)

CloudStack users can add and read comments (annotations) on resources they are authorised to access.  Due to an access validation issue that affects Apache CloudStack versions from 4.16.0, users who have access, prior access or knowledge of resource UUIDs can list and add comments (annotations) to such resources.  An attacker with a user-account and access or prior knowledge of resource UUIDs may exploit this issue to read contents of the comments (annotations) or add malicious comments (annotations) to such resources.  This may cause potential loss of confidentiality of CloudStack environments and resources if the comments (annotations) contain any privileged information. However, guessing or brute-forcing resource UUIDs are generally hard to impossible and access to listing or adding comments isn't same as access to CloudStack resources, making this issue of very low severity and general low impact. CloudStack admins may also disallow listAnnotations and addAnnotation API access to non-admin roles in their environment as an interim measure.

Rincian

Terbit di NVD
13 Januari 2025
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
4.3 (Medium), sumber CISA ADP
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-200: Exposure of Sensitive Information to an Unauthorized Actor
EPSS (30 hari)
2,0% peluang dieksploitasi; lebih tinggi dari 80,0% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
apache cloudstack Versi 4.16.0.0 dan sesudahnya

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.